Parion Sciences Initiates Phase 2 Cystic Fibrosis Study To Test Novel Lung Clearing Therapy
Parion Sciences, a biopharmaceutical company developing treatments to improve and extend the lives of patients with innate mucosal surface defense deficiencies of the eye or lungs, recently announced that it has begun enrollment of patients with Cystic Fibrosis (CF) in a phase 2 clinical trial of its experimental therapy…